66 results
6-K
EX-99.2
THTX
Theratechnologies Inc.
15 Apr 24
Notice of Annual Meeting of Shareholders
9:31am
:
Knowledge by a Board member of one or more persons having the skills, experience, time and commitment required to act as directors
6-K
EX-99.1
THTX
Theratechnologies Inc.
24 Jan 24
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
1:52pm
focused on bringing this new formulation of tesamorelin to market as part of our commitment to innovate and simplify treatments for people with HIV
6-K
EX-99.1
x0sjaqq5 4rh
6 Nov 23
Material Change Report
1:17pm
6-K
lzvms
6 Nov 23
Investor Rights Agreement
12:28pm
6-K
EX-99.6
wugs3bhtuzfe8q nc6so
3 Nov 23
First Amendment to Credit Agreement
2:26pm
6-K
EX-99.1
pfhn qo9z6av7i68p
31 Oct 23
Theratechnologies Announces Closing of US$25 Million Public Offering of
12:51pm
SUPPL
4nfuvkhn4 s60ch
26 Oct 23
Supplemental materials (foreign)
9:13pm
6-K
EX-99.1
52pj13b1r3l7g1 isb
26 Oct 23
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
9:50am
SUPPL
twcl0uc
25 Oct 23
Supplemental materials (foreign)
6:56pm
6-K
EX-99.1
w9gzy m5sa
12 Jul 23
Theratechnologies Reports Second Quarter 2023
8:00am
6-K
EX-99.2
8qfd93oyutac0
13 Apr 23
Notice of Annual Meeting of Shareholders
8:01am
6-K
EX-99.2
7rj2wciug17rwbyu
13 Oct 22
Interim Consolidated Financial Statements
8:01am
6-K
EX-99.1
gwoe34912lco 5suzc1c
13 Oct 22
Theratechnologies Reports Financial Results
7:45am
6-K
EX-99.1
o26g6f9c rykdhdk6g
28 Jul 22
Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement
9:48am
6-K
7s5vb vhepzfr
21 Jul 22
Material Change Report
4:40pm
6-K
EX-99.2
vjns hkzszkw11ps
21 Jul 22
Material Change Report
4:40pm
6-K
EX-99.1
xvnwf iyk4
21 Jul 22
Material Change Report
4:40pm